About Strep
Introduction
The genus Streptococcus was
first identified by Louis Pasteur in 1879 as the bacteria
responsible for puerpal sepsis1. Streptococcus pyogenes,
also known as group A Streptococcus, causes disease of variable
severity, contributing to 20% of tonsillopharyngeal
infections2, and causing impetigo (pyoderma). Left
untreated however, symptoms may become more severe with
complications such as acute rheumatic fever, toxic shock-like
syndrome and glomerulonephritis3. Rapid identification
is therefore important to allow early treatment and prevent disease
progression2.
Streptococcus
pyogenes
Streptococcus pyogenes are
gram positive, facultative anaerobic bacteria. They are often
referred to as β-haemolytic bacteria which relates to the ‘halo’
that surrounds the individual colonies when grown on blood agar.
This occurs as the bacteria produce the toxin streptolysin S, which
gives the bacteria the ability to haemolyse red blood cells and
damage cell membranes. Membrane damage can also occur in
lymphocytes, neutrophils, platelets, and cellular organelles such
as lysosomes and mitochondria4. Streptococcus pyogenes
also has a number of other virulence factors; the most important of
which is the M protein. The M proteins resist phagocytosis by
polynuclear leucocytes and therefore allow the organism to multiply
rapidly in the host. Lipoteichoic acid is also expressed on the
surface of Streptococcus pyogenes and is responsible for the
binding of the organism to fibronectin which is present on the
surface of oral epithelial-cell membranes. Mucoid strains of
Streptococcus pyogenes are surrounded by a capsule that contains
hyaluronic acid, which additionally contributes to the organisms
ability to evade phagocytosis.3
As well as those virulent
factors expressed on the cell surface, there are a number of
extracellular substances Streptococcus pyogenes produce that also
contribute to pathogenesis such as hyaluronidase, neuraminidase,
DNases, streptokinase, pyrogenic exotoxins, streptolysin O and
streptolysin S as described previously. Pyrogenic exotoxins for
example are responsible for the rash in scarlet fever and render
the patient more susceptible to endotoxic shock. Streptolysin O,
DNases and hyaluronidase induce antibody formation approximately 10
to 17 days after infection5.
The majority of streptococci
possess group specific antigens, which are usually carbohydrate
structual components of the call wall. For Streptococcus pyogenes,
the group specific antigen is a polymer of L-rhamose and
N-acetyl-D-glucosamine. Clearview Exact Strep A detects this group
specific carbohydrate antigen, thus confirming the presence of
Group A streptococci (Strep A).
(Reproduced by permission
from Kenneth Todar):
http://textbookofbacteriology.net/streptococcus.html
Epidemiology
Strep A are a major cause of
upper respiratory tract infections in humans. It is thought that
20% of all cases of tonsillopharyngitis are caused by Strep
A2. It typically occurs in young children and infection
rates are particularly high in environments such as schools,
nursing homes and hospitals8,9. The incidence of
infections caused by Strep A is believed to have re-emerged in the
last 10-20 years5,9. In the past, in an effort to reduce
complications such as rheumatic fever and glomerulonephritis,
antibiotics have been prescribed in patients presenting with sore
throats, even in those where there is no proven evidence that the
cause is Strep A and the cause maybe viral2,10. This
approach runs the risk of streptococci developing increased
resistance to antibiotics. To ensure this does not happen, the use
of rapid diagnostic tests is important.
Diagnosis
A specimen should be
obtained by standard throat swab collection methods. The recovery
of Strep A is dependent on the quality of the specimen collected. A
tongue depressor and light should be used along with a good
technique that swabs all areas at the back of the throat. This can
increase he recovery of organisms ten-fold.
Culture:
Traditional methods for the
identification of Strep A depend on the isolation and subsequent
identification of the organisms. Throat swabs are cultured onto
solid agar (e.g. tryptose or columbia agar) supplemented with
either 5% horse or sheep blood11. The agar plates are
then incubated for 18-24 hours at 37°C aerobically with the
addition of 5% CO2 or anaerobically. Agar supplemeted with sheep
blood has the advantage that it does not support the growth of
Haemophillius haemolyticus which show similar colonial morphology
when grown on sheep blood agar under aerobic conditions, therefore
anaerobic conditions are favoured. Strep A are typically 0.5mm in
diameter and are surrounded by a zone of complete
haemolysis13.
The haemolytic action of
streptococci on erythrocytes was first described by Brown in 1919.
There are 4 recognised haemolysis patterns:
- Alpha haemolysis: Partial heamolysis observed around the
colonies, the growth medium may be slightly discoloured.
- Beta haemolysis: Complete haemolysis observed with a clear,
colourless zone surrounding colonies.
- No haemolysis: No apparent haemolysis or discoloration of the
agar surrounding the colonies.
- Alpha-prime or wide zone alpha haemolysis: A small area of
partially lysed cells next to the bacterial colony with a zone of
complete haemolysis extending out into the medium.
Browns method has been used
to characterise streptococcal groups from culture plates but it is
limited in that other groups of streptococci also produce
β-haemolytic colonies13.
Selective media can also be
used for the isolation of Strep A e.g. SXT blood agar (blood agar
containing sulfamethoxazole and trimethoprim). This media has
limitations in that despite being a selective agar for Strep A,
other streptococci may also grow in small numbers. Also a few
strains of Strep A are susceptible to SXT and generally a second
day of incubation is required for optimal recovery of Strep
A14.
Following culture, all
β-haemolytic organisms are confirmed with a streptococcal grouping
kit.
Serological
Testing:
Streptococci can also be
identified according to their cell wall antigen, which is specific
for each Streptococcus group. This classification system was first
described by Rebecca Lancefield in 193314. There are
many commercially available streptococcal kits including latex
agglutination tests. The streptococcal group antigens are extracted
from the cells (β-haemolytic colonies of streptococci) and their
presence demonstrated with latex particles previously coated with
group-specific antibodies. The latex particles will agglutinate in
the presence of the homologous antigen, but no agglutination will
occur in the presence of such antigen. The streptococcal grouping
kits allow the identification of streptococcal groups, A, B, C, D,
F and G.
Serological identification
of Group A ß -Haemolytic Streptococcus by the M protein is the most
specific marker and therefore regarded as the ‘gold standard’ for
reliable strain identification11.
Rapid Immunoassay –
Clearview Strep A
Clearview Strep A can rapidly
identify Group A Streptococcus by a rapid immunoassay method. This
method employs an extraction procedure, followed by a rapid test
procedure, generating a visually read result.
The group A streptococcal
specific antigen is extracted using nitrous acid. The swab
specimen is added to the extraction mixture. Specimens should
be collected using dacron tipped swabs and no transport media used.
If group A Streptococcus is present in the sample, the nitrous acid
will break down the cell wall releasing the antigen
L-rhamose-N-acetylglucosamine. The resultant extract is then
neutralised.
The neutralised extraction
mixture is added to the Sample Window of a Clearview Strep
A device. The Sample Window contains antibody labelled
latex particles specific for group A Streptococcus carbohydrate
antigen. If group A Streptococcus is present, antigen released from
the cell wall during the extraction process binds to the antibody
labelled latex particle. This complex moves along the test strip by
capillary action and binds to a region of immobilised rabbit
anti-group A Streptococcus antibody in the Result Window, forming a
blue line. If no antigen is present, the Result Window will remain
clear.
Clearview Strep
A also provides an integral control feature. The test
strip also contains a region of goat anti-rabbit antibodies. Latex
labelled rabbit antibodies present in the Sample Window travel
along the test strip by capillary action and binds to the region of
immobilised goat anti-rabbit antibody in the Control Window forming
a blue line. The appearance of a blue line in the Control Window
shows the test has worked correctly.
References
- Efstratiou A. (2000) Group A streptococci in the 1990s. Journal
of Antimicrobial Chemotherapy. 45,Topic T1, 3-12.
- Adam D. (2000) Group A beta-haemolytic streptococcal (GABHS)
tonsillopharyngitis is still a common problem. Journal of
Antimicrobial Chemotherapy. 45, Topic T1, 1-2.
- Bisno A. L. (1991) Group A Streptococcal Infections and Acute
Rheumatic Fever. The New England Journal of Medcine. 325(11),
783-793.
- Nizet V., Beall B., Bast D.J., Datta V., Kilburn L., Low D.E.
& De Azevedo J.C.S. (2000) Genetic Locus for Streptolysin S
Production by Group A Streptococcus. Infection and Immunity. 68(7),
4245-4254.
- Kiselica D. (1994) Group A Beta-Haemolytic Streptococcal
Pharyngitis: Current Clinical Concepts. American Family Physician.
49(5), 1147-1154.
- Heath A., DiRita V.J., Barg N.L. & Engleberg N.C. (1999) A
Two-Component Regulatory System, CsrR-CsrS, Represses Expression of
three Streptococcus Pyogenes Virulence factors, Hyaluronic acid
capsule, Streptolysin S, and Pyogenic Exotoxin B. Infection and
Immunity. 67(10), 5298-5305.
- Woods W.A., Carter C.T. & Schlager T.A. (1999) Detection of
Group A streptococci in children under 3 years of age with
pharyngitis: Paediatric Emergency care. 15(5), 338-340.
- Schwartz B., Elliot J.A., Butler J.C., Simon P.A., Jameson
B.L., Welch G.E. & Facklam R.R. (1992) Clusters of Invasive
Group A Streptococcal Infections in family, hospital and nurse home
settings: Clinical infectious Diseases. 15, 277-84.
- O’Brien K.L., Beall B., Barrett N.L., Cieslak P.R., Reingold
A., Farley AM.M., Danila R., Zell E.R., Facklam R., Scwartz B.
& Schuchat A. (2002) Epidemiology of Invasive Group A
Streptococcus Disease in the United States, 1995-1999. Clinical
Infectious Diseases. 35, 268-276.
- Little P.S., Williamson I. (1994) Are antibiotics appropriate
for sore throats? Costs outweigh the benefits. British Medical
Journal. 309, 1010-1011.
- Kaufhold A. & Ferrieri P. (1993) The Microbiological
Aspects, Including Diagnosis, of β-Hemolytic Streptococcal and
Enterococcal Infections. Laboratory Diagnosis of Infectious
Diseases. 7(2), 235-256.
- Ross P.W. (1971) Throat Swabs and Swabbing Technique. The
Practitioner. 207, 791-796.
- Facklam R.R. & Washington J.A. II (1991) Streptococcus and
related catalase negative gram positive cocci: In: Balows A.,
Hausler W.J. Jr, Herrmann K.L., et al (eds): Manual of Clinical
Microbiology, ed 5. Washington, DC, American Society for
Microbiology: 238-257.
- Lancefield R.C. (1933) A Seriological Differentiation of
Human and Other Groups of Hemolytic Streptococci. J.Exp.Med. 57,
571-593.